Paula Montero
Overview
Explore the profile of Paula Montero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Montero P, Roger I, Estornut C, Milara J, Cortijo J
Heliyon
. 2023 May;
9(5):e15613.
PMID: 37144195
-Acetyl-l-cysteine (NAC) acts as a precursor of the tripeptide glutathione (GSH), one of the principal cell mechanisms for reactive oxygen species (ROS) detoxification. Chronic obstructive pulmonary disease (COPD) is associated...
12.
Roger I, Montero P, Perez-Leal M, Milara J, Cortijo J
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831549
Nowadays, clinical practice encounters the problem of delayed-type hypersensitivity (DTH) induced by several drugs. Antineoplastic treatments are among the drugs which show an elevated proportion of DHT reactions, leading to...
13.
Peiro T, Alonso-Carpio M, Ribera P, Almudever P, Roger I, Montero P, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499646
Skin fibrosis is a hallmark of a wide array of dermatological diseases which can greatly impact the patients' quality of life. Galectin-3 (GAL-3) has emerged as a central regulator of...
14.
Milara J, Martinez-Exposito F, Montero P, Roger I, Bayarri M, Ribera P, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36498845
Inflammasome activation is one of the first steps in initiating innate immune responses. In this work, we studied the activation of inflammasomes in the airways of critically ill COVID-19 patients...
15.
Milara J, Roger I, Montero P, Artigues E, Escriva J, Cortijo J
Respir Res
. 2022 Nov;
23(1):313.
PMID: 36376885
Background: Pulmonary hypertension (PH) associated to idiopathic pulmonary fibrosis (IPF) portends a poor prognosis. IL-11 has been implicated in fibrotic diseases, but their role on pulmonary vessels is unknown. Here...
16.
Roger I, Montero P, Garcia A, Milara J, Ribera P, Perez-Fidalgo J, et al.
Pharmaceuticals (Basel)
. 2022 Sep;
15(9).
PMID: 36145332
Delayed-type hypersensitivity (DTH) is caused by a broad number of drugs used in clinic, and antineoplastic drugs show an elevated proportion of DTH, which potentially affects the quality of life...
17.
Ortiz-Zapater E, Signes-Costa J, Montero P, Roger I
Biomedicines
. 2022 Jun;
10(6).
PMID: 35740444
In the lungs, fibrosis is a growing clinical problem that results in shortness of breath and can end up in respiratory failure. Even though the main fibrotic disease affecting the...
18.
Montero P, Perez-Leal M, Perez-Fidalgo J, Sanz C, Estornut C, Roger I, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267454
Background: Paclitaxel is a microtubule-stabilizing chemotherapeutic agent. Despite its widespread use, it damages healthy tissues such as skin. The goal of this study was to prove that the real impact...
19.
Montero P, Milara J, Perez-Leal M, Estornut C, Roger I, Perez-Fidalgo A, et al.
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163066
Paclitaxel is a microtubule-stabilizing chemotherapeutic agent approved for the treatment of ovarian, non-small cell lung, head, neck, and breast cancers. Despite its beneficial effects on cancer and widespread use, paclitaxel...
20.
Montero P, Milara J, Roger I, Cortijo J
Int J Mol Sci
. 2021 Jul;
22(12).
PMID: 34207510
Interstitial lung diseases (ILDs) comprise different fibrotic lung disorders characterized by cellular proliferation, interstitial inflammation, and fibrosis. The JAK/STAT molecular pathway is activated under the interaction of a broad number...